The U.S. FDA cleared Medtronic’s Hugo robotic‑assisted surgery (RAS) system and CMR Surgical’s Versius Plus system for the U.S., expanding hospital options beyond the longstanding da Vinci platform. The clearances come as demand for minimally invasive robotic procedures grows and hospitals seek alternative suppliers amid pricing and capacity pressures. New entrants could change procurement dynamics and competitive positioning in soft‑tissue surgery. Health systems will evaluate clinical workflows, training needs and maintenance models as they add competing robotic platforms.